Pereiti į pagrindinį turinį
Kesimpta

Please select your country (language)

Austria (Deutsch)

Belgium (Nederlands)

Denmark (Dansk)

France (Français)

Iceland (Islenska)

Lithuania (Lietuvių kalba)

Malta (Malti)

Portugal (Português)

Spain (Español)

Bulgaria (Български)

Croatia (Hrvatski)

Estonia (Eesti keel)

Germany (Deutsch)

Ireland (English)

Luxembourg (Français)

The Netherlands (Nederlands)

Romania (Română)

Sweden (Svenska)

Belgium (Français)

Cyprus (Ελληνικά)

Finland (suomi)

Greece (Ελληνικά)

Italy (Italiano)

Luxembourg (German)

Norway (Norsk)

Slovakia (Slovenčina)

UK-Northern Ireland (English)
 

Belgium (Deutsch)

Czech Republic (Česky)

Finland (Svenska)

Hungary (Magyar)

Latvia (Latviešu valoda)

Malta (English)

Poland (Polski)

Slovenia (slovenščina)

Legal-Lithuania
  • Naudojimo sąlygos
  • Slapukų politika
  • Slapukų nuostatos
© 2025 Novartis BS2207268229 2022 m. liepos mėn

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please refer to the Package Leaflet for more information.